Polpharma Selects IQVIA’s Orchestrated Customer Engagement Platform to Improve Salesforce Productivity

0

RESEARCH TRIANGLE PARK, NC – (COMMERCIAL THREAD(OCE) to be deployed in 12 Central and Eastern European countries, including Poland and Russia.

Markus Sieger, CEO of Polpharma Group, said: “This investment is part of Polpharma’s 2021-2025 growth strategy and will be essential to help the Polpharma Group cope with market changes and streamline our business operations while creating more impactful customer interactions.

IQVIA OCE gives life science companies full visibility and understanding of their interactions with their customers and helps them connect with customers across all channels. OCE also improves productivity by automating administrative and repetitive tasks with its artificial intelligence and machine learning (AI / ML) capabilities. OCE will enable Polpharma to improve the productivity of its sales force and accelerate the deployment of multi-channel digital marketing campaigns to customers.

“We are proud to support Polpharma Group in its transformation towards a new model of customer engagement,” said Alistair Grenfell, President Europe, Middle East, Africa and South Asia of IQVIA. “The OCE solution will help Polpharma strengthen its market position and deliver a superior and orchestrated customer experience, delivering more value to patients and customers. ”

About the Polpharma Group

Polpharma Group BV supplies high quality and affordable medicines to communities in Central and Eastern Europe, Russia and other CIS markets. We have a leading market position in Poland and Central Asia while being one of the five fastest growing pharmaceutical companies in Russia. In addition to business partnerships across Europe and the rest of the world on our current and future portfolio.

Every day, we diligently cooperate with physicians, pharmacists and other healthcare professionals to better understand every step of a patient’s journey and to ensure that our patients receive and adhere to the most adequate treatment. We do this by building strong capabilities around therapeutic areas to bring value to our clients so that they can deliver greater value to patients.

With the best talent in the industry and cutting-edge digital technologies, we are able to design and deliver products and solutions essential to solving the biggest health and healthcare system challenges. Through the collaboration between Polpharma Group BV and IQVIA on a new CRM system (OCE), we are further leveraging the service and value we bring to a changing healthcare environment and the needs of healthcare professionals. www.polphamagroup.com.

About IQVIA

IQVIA (NYSE: IQV) is a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry. IQVIA creates smart connections across all aspects of healthcare through its analytics, transformative technology, big data resources, and vast domain expertise. IQVIA Connected Intelligence ™ delivers powerful information with speed and agility, enabling customers to accelerate the clinical development and commercialization of innovative medical treatments that improve healthcare outcomes for patients. With approximately 74,000 employees, IQVIA operates in more than 100 countries.

IQVIA is a world leader in protecting patient privacy. The company uses a wide variety of technologies and privacy protections to protect the privacy of individuals while generating and analyzing information at a scale that helps healthcare stakeholders identify disease patterns and correlate with the precise treatment path and therapy needed for best results. IQVIA’s knowledge and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders better understand diseases, behaviors human beings and scientific advances, with the aim of advancing towards treatments. To learn more, visit www.iqvia.com.


Source link

Leave A Reply

Your email address will not be published.